Expertise in
1
conditions

Yu Ren

277 Yanta Western Road, 
Xi'an, CN 
Expertise in
1
conditions
277 Yanta Western Road, 
Xi'an, CN 

Overview

Yu Ren practices practicing medicine in Xi'an, China.

Ren is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Breast Cancer, Breast Cancer in Men, BRCA Positive Breast Cancer, Breast Infection, and Mastectomy.

They are actively involved in clinical research, co-authoring 82 peer reviewed articles and participating in 3 clinical trials.

Locations

277 Yanta Western Road, Xi'an, 710061, China
Other Locations
No. 277 Yanta West Road, Xi'an, 710061, China
277 West Yanta Road, Xi'an, 710061, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer
A Open-label, Multicenter Phase II Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With HR-positive, HER2-negative Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: April 08, 2026
Intervention Type: Drug
Study Drugs: TQB3616 Capsules, Fulvestrant Injection
Study Phase: Phase 2
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
eMonarcHER: A Randomized, Double Blind, Placebo-Controlled Phase 3 Study of Abemaciclib Plus Standard Adjuvant Endocrine Therapy in Participants With High-Risk, Node-Positive, HR+, HER2+ Early Breast Cancer Who Have Completed Adjuvant HER2-Targeted Therapy
Enrollment Status: Terminated
Publish Date: July 15, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
View 1 Less Clinical Trial

82 Total Publications

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.
Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial.
Journal: JAMA oncology
Published: September 03, 2026

Frequently Asked Questions about Yu Ren

Is Yu Ren a top-rated expert for Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Yu Ren is classified as an Advanced expert for Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Yu Ren participate in research or clinical trials?

Yes. Yu Ren has published 82 articles and abstracts on conditions like Breast Cancer. You can view a list of Yu Ren's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ren's expertise for a condition
ConditionClose
      View All 10 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile